Concepcion Boque

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.

One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.

Journal: Annals of hematology
Published: August 14, 2025

Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations.

Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations.

Journal: Journal of clinical medicine
Published: August 07, 2023

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.

Journal: Cancers
Published: January 17, 2023

Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients.

Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients.

Journal: Journal of clinical medicine
Published: September 09, 2022

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.

Journal: Annals of hematology
Published: April 19, 2022

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib.

Journal: Journal of clinical medicine
Published: June 15, 2021

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients.

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients.

Journal: HemaSphere
Published: May 07, 2021

A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection.

A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection.

Journal: Bone marrow transplantation
Published: May 05, 2021

The direct and indirect effects of COVID-19 pandemic in a real-life hematological setting.

The direct and indirect effects of COVID-19 pandemic in a real-life hematological setting.

Journal: Cancer reports (Hoboken, N.J.)
Published: December 09, 2020

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.

Journal: Blood cancer journal
Published: November 09, 2020

miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk.

miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk.

Journal: Leukemia
Published: August 02, 2019

Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms.

Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms.

Journal: American journal of hematology
Published: June 19, 2019
Showing 1-12 of 25

Last Updated: 09/26/2026